Drugs that contain Teduglutide Recombinant

1. List of Gattex Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056886 NPS PHARMS INC GLP-2 formulations
Sep, 2022

(4 months ago)

US7056886

(Pediatric)

NPS PHARMS INC GLP-2 formulations
Mar, 2023

(a month from now)

US9974835 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9555079 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9987334 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9060992 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9981016 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9968656 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9987335 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9592274 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9974837 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9981014 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US7847061 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9545434 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9968655 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9572867 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9993528 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9968658 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9545435 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9592273 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US9539310 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
Nov, 2025

(2 years from now)

US7847061

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9060992

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9592274

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9592273

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9572867

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9987335

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9993528

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9981016

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9968658

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9974835

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9974837

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9968656

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9968655

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9987334

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9981014

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9539310

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9545435

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9545434

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

US9555079

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity
May, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 16, 2026

Market Authorisation Date: 21 December, 2012

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in